Importance of standardized stepwise screening in patients with resistant hypertension;Važnost sistemskog probira u algoritmu dijagnostike rezistentne hipertenzije

Acta Medica Croatica

Volumn 68, Issue 2, 2014, Pages 111-115

  Prkačin, Ingrid ^a   Balenovic, Diana ^b   Cavrić, Gordana ^a   Bartolek, Dubravka ^c   Bulum, Tomislav ^a  

^a University of Zagreb   (Croatia)

^b Sisak General Hospital Department of Internal Medicine   (Germany)

^c Sv Katarina Special Hospital   (Croatia)

Author keywords

Resistant hypertension; Stepwise screening protocol

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

AGE; ARTICLE; AUTONOMIC DYSFUNCTION; CHRONIC KIDNEY DISEASE; DIABETIC NEUROPATHY; FOLLOW UP; HUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; RESISTANT HYPERTENSION; SALT INTAKE; SCREENING; SLEEP DISORDER; SLEEP DISORDERED BREATHING; ADULT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; COMORBIDITY; HYPERTENSION; MALE; MASS SCREENING; PREVALENCE; PROCEDURES; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STANDARDS;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; COMORBIDITY; HUMANS; HYPERTENSION; MALE; MASS SCREENING; OBESITY; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84931081992     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mancia G, Fagard R, Narkiewicz K i sur. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
2. Calhoun DA, Jones D, Textor S i sur. Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.
3. Kaplan NM, Sica DA Resistant hypertension. U: Izzo JL, Sica DA, Black Hr i sur. Hypertension primer, 4.izd. Philadelphia: Lippincott Williams & Wilkins, 2008, 248-350.
4. Schlaich MP, Sobotka PA, Krum H, Whitbourn R., Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195-1201
5. Epstein M. Resistant hypertension: prevalence and envolving concept. J Clin Hypertens 2007; 9: 2-6.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes ih high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
7. Balck HR, Elliot WJ, Grandits G i sur. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-82.
8. Julius S, Kjeldsen SE, Brunner H i sur. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-8.
9. Sarafidis PA, Bakris GL Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749-57.
10. Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens 2007; 9: 13-18.
11. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controling resistant hypertension. J Clin Hypertens 2007; 9: 19-24.
12. Cuspidi C, Macca G, Sampieri L., Michev I, Salerno M, Fusi V. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-70.
13. Park J, Campese V. Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens 2007; 9: 7-12.
14. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol 2007; 88: 683-92.
15. Prkačin I., Balenović D, Jurina A i sur. Učestalost rezistentne hipertenzije u hipertenzivnih nedijabetićkih kronićnih bubrežnih bolesnika (I-IV stadij) je podcijenjena. Acta Med Croatica 2012; 66(supl 3): 229-33.
16. Hering D, Mahfoud F, Walton AS i sur. Renal Denervation in Moderate to Severe CKD. J Am Soc Nephrol 2012; 23: 1250-7.
17. Prkačin I., Marković M, Cavrić G, Vidjak V Successful treatment of resistant hypertension with renal denervation treatment in a patient with multiple morbidities including multivesssel atherosclerotic disease, chronic kidney disease and glucose intolerance. Neurol Croat 2013; 62 (Suppl 2): 11-14.
18. Prkačin I., Mileta D, Cavrić G, Krtanjek S, Perkov S, Flegar-Meštrić Z. Significance of serum creatinine standardization and estimated glomerular filtration rate reporting in patients with resistant hypertension. Neurol Croat 2013; 62 (Suppl 2): 41-4.
19. Matteucci E, Giampietro O. Circadian Rhythm of Blood Pressure in Diabetes mellitus: Evidence, Mechanism and Implications. Curr Diabetes Rev 2012; 8: 355-61.